Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension CAMBRIDGE, Mass., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Tarix Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted TXA127, the Company's lead peptide drug...